NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study of Bevacizumab With Taxane Therapy in Participants With Triple Negative Breast Cancer

CompletedPhase 4

Sponsor: Hoffmann-La Roche

Conditions: Breast Cancer

Interventions: Bevacizumab, Paclitaxel, Docetaxel

Countries: United Kingdom

This open-label, multi-center study will evaluate the safety, tolerability and effect of bevacizumab (Avastin) in combination with taxane (paclitaxel/ docetaxel) monotherapy on disease progression, survival time and Karnofsky performance status in female participants with estrogen-, progesterone- and human epidermal growth factor receptor 2 (HER2)-negative (triple-negative) breast cancer.

Eligibility overview

Sex: FEMALE

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Histologically confirmed triple-negative (estrogen, progesterone, and HER-2 receptor negative) adenocarcinoma of the breast in pre- or post-menopausal women with measurable or non-measurable metastatic disease
* Participant who in the Investigator's opinion requires combination therapy for their disease
* Life expectancy of greater than or equal to (\>/=)12 weeks

Exclusion Criteria:

* Previous chemotherapy for metastatic breast cancer
* Participants currently undergoing radiation therapy for the treatment of metastatic disease (apart from the relief of metastatic bone pain)
* Major surgery or significant traumatic injury within 28 days prior to enrollment or anticipation of the need for major surgery during study treatment

Locations (10)

Bangor, United Kingdom
Cottingham, United Kingdom
Exeter, United Kingdom
Grimsby, United Kingdom
Harrogate, United Kingdom
Plymouth, United Kingdom
Portsmouth, United Kingdom
Preston, United Kingdom
Somerset, United Kingdom
Wolverhampton, United Kingdom